during pregnancy without prior testing in pregnant women, which resulted in unforeseen teratogenic effects with severe birth defects in over 10,000 children. 2 Even though neither tragedy involved clinical research, these events had a great impact on the research community, which at the time was already characterized by a determination to protect allegedly vulnerable populations, including pregnant women, from research participation. The protectionist approach is one of the reasons for the existing precautionary attitude with regard to including pregnant women in clinical research today.
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Although concerns about fetal well-being are valid, at the same time there is a need for evidence-based information on medications and treatments for pregnant women, because 'pregnant women get sick, and sick women get pregnant'. 4 In the absence of evidence-based knowledge, clinicians may have to prescribe offlabel medications without evidence or based on contradictory evidence, 5 or clinicians or pregnant women themselves may choose to discontinue medically important medications. 6 The result of under-representation of pregnant women in clinical research is a harmful situation, leaving pregnant women at risk for potentially avoidable therapeutic incidents. 7 For example, poorly treated asthma and untreated depression are problematic for pregnant women and fetuses: both are associated with premature birth, low birthweight and fetal growth restriction and, in the case of asthma, a higher risk of hypertension and pre-eclampsia. 8 Physiological changes during pregnancy alter the way that drugs are processed by the body and the ways that drugs act on the body in a fashion difficult to predict from the pharmacokinetics and pharmacodynamics in men and non-pregnant women. Moreover, information about teratology and toxicity is often difficult to extrapolate and interpret from preclinical data or studies in non-pregnant humans. 9 Gathering conclusive data to enable evidence-based therapeutic decisions for pregnant women therefore requires research in the population of pregnant women in order to develop effective treatments for pregnant women with acute or chronic obstetric and non-obstetric illnesses. tional ethical guidelines, in this paper we will limit our scope to the CIOMS guidelines. 18 We will analyse how these guidelines may help to break down the status quo pertaining to the evidence base and hence contribute to fair inclusion of pregnant women in research.
| FAIR IN CLUS I ON AND THE CI OMS G UIDELINE S
At least three aspects of the revised CIOMS guidelines may affect fair inclusion of pregnant women in research.
| Pregnant women are not vulnerable per se
Unlike some other guidance documents, the CIOMS guidelines 
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. 21 In sum, CIOMS' explicit claim to not regard pregnant women as vulnerable may help to strengthen research into the health needs of pregnant women.
| Promote research relevant to the health needs of pregnant women
The CIOMS guidelines now claim that 'research designed to obtain knowledge relevant to the health needs of the pregnant and breastfeeding woman must be promoted' (Guideline 19). Analogous to the guidelines on children and adolescents (Guideline 17) and on individ- does not follow in Guideline 19 that they must be included in healthrelated research unless a good scientific reason justifies their exclusion. In other words, unlike several bioethicists, 22 the CIOMS guidelines do not go so far that routine inclusion of pregnant women in research must be promoted, nor that the default position is to include them unless there is a scientific reason to justify exclusion.
At first sight, the CIOMS guidelines may seem to be inconsistent in Guideline 19, since it does not require justifications of exclusion as written in the guidelines on children and incompetents. At the same time, from a methodological viewpoint, the formulation to promote research may function as a stronger (positive) protection of the health interests of pregnant women and fetuses. Since data on medication use in pregnant women is so scarce, pregnant women will virtually always substantially differ from other populations like children and incompetents. Methodologically, it makes no sense to add a few pregnant women to a population that primarily exists of nonpregnant women when the factor pregnancy is not taken into account. In those cases, trials should either be conducted separately in pregnant women, or a larger trial should be designed with prespecified subgroup analyses that studies the effects of the intervention in the two groups of women separately. 23 Moreover, if we know or assume that intervention effects in pregnant women and non-pregnant women will differ, then an estimated overall effect is not informative since it does not apply to non-pregnant women or pregnant women, only to a population with a similar distribution of these subgroups. 24 In other words, 'promotion of research on pregnant women' is a stronger protection than having to justify their exclusion. On the one hand, pregnant women are not unnecessarily included in trials that do or cannot take the pregnancy factor into account in the anal- In sum, the claim that research relevant to the health needs of pregnant women must be promoted focuses on a broader group of stakeholders to protect the health interests of pregnant women than protection by RECs alone.
| Clarified levels of acceptable research risks
In the 2002 version of the CIOMS guidelines the level of acceptable research risks for pregnant women and fetuses remained unclear. 28 The guideline left it up to pregnant women themselves to decide whether research risks were acceptable: 'the decision about acceptability of risk to the fetus should be made by the woman as part of the informed consent process'. In 2016, the risk threshold has been clarified and reads as follows:
For research interventions or procedures that have the potential to benefit either pregnant or breastfeeding women or their fetus or infant, risks must be minimized and outweighed by the prospect of potential individual benefit. Furthermore, consistent with Guideline 4 on research risks and potential benefits, we argue that the surgery should be able to go forward if:
1. The risks to the fetus are outweighed by the potential benefits to the fetus and the woman. Even if the risks to the woman are high, the net risks for both the woman and the fetus may be regarded as acceptable in light of the direct physical benefits to be expected for both the woman and the fetus.
2.
The risks to the woman are reasonable in relation to the potential benefits for the fetus and the social value of the research.
3.
The risks to the woman respect some upper risk limits that researchers and RECs should further specify in concrete cases.
Analogies that RECs may take into account are comparable upper risk thresholds in the case of altruistic organ donation and research with competent consenting participants.
In sum, the now clarified threshold for acceptable research risks may help to prevent pregnant women being unnecessarily excluded from research.
| D ISCUSS I ON
The 2016 CIOMS guidelines contribute to fair inclusion of pregnant women in research to the extent that pregnant women are explicitly not seen as vulnerable, research relevant to their health needs is promoted, and acceptable levels of risk have been clarified.
Moreover, since pregnant women are still under-represented in research and the status quo in knowledge generation for medications and treatments of pregnant women is substantial, it seems justified to maintain a separate guideline on the interests of pregnant women as research participants.
Evidently, fair inclusion of pregnant women will not be achieved by clarification of guidance documents alone. For instance, while guidelines such as CIOMS have widened the possibility for research with pregnant women, interpretation and perception of such documents is something different. Mechanisms of over-and underprotection play a role. An example of overprotection is that healthcare professionals may be reluctant to include pregnant women because they perceive a study to be high risk, even though an REC classifies the study as low risk. 31 Underprotection also applies in the sense that research and care have become totally distinct worlds in the field of drug use in pregnancy. Paradoxically, pregnant women are excluded from research for protection, while they run high risks in routine practice, yet without learning from this exposure to protect future medication users. A potential solution for both over-and underprotection of pregnant women taking medications during pregnancy is to transform the field into a so-called learning health system (LHS). As we argued above, since CIOMS Guideline 19 is structured as a guideline that is primarily focused on priority and agenda set- Another crucial factor to realize transformation to an LHS is However, these data sources are not designed to combine data on the drug used, endpoints to determine efficacy and safety of the drug used to treat, birth defects and potential long-term consequences of use of the specific medicines during pregnancy. This meta-registry is essential for clinical practice, since physicians and women are not only interested in teratogenicity, but also in adverse maternal and fetal events, related to either using or not using a drug.
For instance, the risk on teratogenicity should be weighed against risks of serious infections for the neonate when medication is dis- Third, we have to take a co-creationistic approach. One explanation for the continuing status quo is the lack of ownership of the
